Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.49
-1.13 (-5.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 501 | 654 | 187 | 489 | 865 | 1,861 | |
| Market Cap Growth | 287.18% | 249.70% | -61.73% | -43.52% | -53.52% | - | |
| Enterprise Value | 305 | 379 | -215 | -45 | 182 | 992 | |
| Last Close Price | 21.49 | 30.78 | 12.80 | 38.80 | 69.40 | 154.80 | |
| PS Ratio | 13925.75 | 18163.58 | 3065.30 | 3758.66 | 10.22 | 174.77 | |
| PB Ratio | 1.84 | 2.64 | 0.49 | 0.75 | 1.04 | 2.00 | |
| P/TBV Ratio | 2.02 | 2.64 | 0.49 | 0.75 | 1.04 | 2.00 | |
| EV/Sales Ratio | 8475.03 | 10515.28 | - | - | 2.15 | 93.15 | |
| Debt / Equity Ratio | 0.21 | 0.21 | 0.15 | 0.10 | 0.08 | 0.07 | |
| Net Debt / Equity Ratio | -0.79 | -0.79 | -0.85 | -0.76 | -0.77 | -0.89 | |
| Net Debt / EBITDA Ratio | 1.05 | 1.05 | 1.63 | 2.22 | 3.80 | 4.15 | |
| Net Debt / FCF Ratio | 1.30 | 1.30 | 1.99 | 3.00 | 3.32 | 4.33 | |
| Asset Turnover | 0 | 0 | 0 | 0 | 0.08 | 0.01 | |
| Quick Ratio | 5.00 | 5.00 | 6.89 | 15.82 | 17.29 | 13.15 | |
| Current Ratio | 5.28 | 5.28 | 7.06 | 16.07 | 17.59 | 13.40 | |
| Return on Equity (ROE) | -86.98% | -86.98% | -66.10% | -31.53% | -20.77% | -30.36% | |
| Return on Assets (ROA) | -29.83% | -29.83% | -22.05% | -18.18% | -11.32% | -13.11% | |
| Return on Capital Employed (ROCE) | -68.20% | -68.20% | -50.10% | -34.30% | -20.80% | -19.80% | |
| Earnings Yield | -54.74% | -41.97% | -183.44% | -48.02% | -21.17% | -13.44% | |
| FCF Yield | -30.08% | -23.06% | -87.10% | -34.05% | -22.40% | -10.30% | |
| Buyback Yield / Dilution | -30.74% | -30.74% | -4.18% | -1.58% | -81.79% | -925.18% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.